Rivaroxaban use in patients with antiphospholipid syndrome and previous venous thromboembolism

Blood Coagulation and Fibrinolysis

Volumn 26, Issue 4, 2015, Pages 476-477

  Savino, Sciascia ^a,b   Breen, Karen ^a   Hunt, Beverley J ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RIVAROXABAN; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; DRUG USE; ESOPHAGUS VARICES; HUMAN; INTERNATIONAL NORMALIZED RATIO; LETTER; LIVER CIRRHOSIS; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; SECONDARY PREVENTION; SYSTEMIC LUPUS ERYTHEMATOSUS; VENOUS THROMBOEMBOLISM; ADOLESCENT; ADULT; AGED; ANTAGONISTS AND INHIBITORS; FEMALE; MALE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; FACTOR XA INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; RIVAROXABAN; VENOUS THROMBOEMBOLISM; VITAMIN K; YOUNG ADULT;

EID: 84929471149     PISSN: 09575235     EISSN: 14735733     Source Type: Journal    
DOI: 10.1097/MBC.0000000000000247     Document Type: Letter

References (7)

1. Sensoy B, Canpolat U, Cay S, Ozeke O, Açkgö z K, KuşO, et al. Treatment of mechanical valve thrombosis in the right heart: overview of the requirements for the new thrombolytic protocols. Blood Coagul Fibrinolysis 2014; September 24, 2014 doi:10.1097/MBC.0000000000000215.
2. Vahanian A, Baumgartner H, Bax J, Butchart E, Dion R, Filippatos G, et al. Guidelines on the management of valvular heart disease: the Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28:230-268.
3. Bonow RO, Carabello BA, Chatterjee K, de Leon AC Jr, Faxon DP, Freed MD, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2008; 52:e1-e142.
4. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuunemann HJ. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis 9th ed.: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:7S-47S.
5. Lengyel M, Horstkotte D, Voller H, Mistiaen WP. Recommendations for the management of prosthetic valve thrombosis. J Heart Valve Dis 2005; 14:567-575.
6. Özkan M, Gündü z S, Biteker M, Astarcioglu MA, Ç evik C, Kaynak E, et al. Comparison of different TEE-guided thrombolytic regimens for prosthetic valve thrombosis: the TROIA trial. JACC Cardiovasc Imaging 2013; 6: 206-216.
7. Kalçk M, Gü rsoy OM, Astarcog lu MA, Ozkan M. A serial fluoroscopyguided thrombolytic therapy of a mechanical tricuspid prosthetic valve thrombosis with low-dose and ultra-slow infusion of tissue-type plasminogen activator. Turk Kardiyol Dern Ars 2014; 42:478-481.